Literature DB >> 28456734

Thermosensitive Gel-Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197.

Amir Fakhari1, Sean Nugent2, James Elvecrog3, John Vasilakos3, Marta Corcoran4, Ashenafi Tilahun3, Kristen Siebenaler3, Jenny Sun5, J Anand Subramony4, Alexander Schwarz4.   

Abstract

Toll-like receptor (TLR) agonists TLR 7/8, MEDI9197, is a imidazoquinoline analogue that can be used for cancer immunotherapy based on its efficacy toward a variety of tumors. Systemic administration of TLR agonists results in stimulation of the immune system throughout the entire body causing undesirable side effects. To minimize these adverse events, local administration of TLR agonists including intratumoral (IT) delivery has been introduced. Here, a poloxamer 407 thermogel formulation for IT delivery of a TLR 7/8 dual agonist, MEDI9197, is described in which the combination of the aqueous thermogel and the ethanolic TLR 7/8 dual agonist, MEDI9197, solution leads to precipitated drug particles within the gel. The in vitro release profile showed an initial burst followed by sustained release. A B16-OVA mouse tumor model was used to assess the in vivo pharmacokinetics, efficacy, and systemic cytokine and chemokine (cytokine) production of the poloxamer 407-based thermogel formulation. The pharmacokinetic evaluation showed that the agonist level within the tumor was reduced by ∼70% over 14 days while serum agonist levels indicated an initial burst at the 6-h time point followed by a drop in serum drug levels over the 14 days of the experiment. The tumor growth inhibition, survival, and serum cytokines for post-IT injection of the poloxamer 407 formulation showed that it slowly released TLR 7/8 agonist, MEDI9197, resulting in more efficacious tumor growth inhibition compared with control groups. In addition, the cytokine levels in circulation indicated that a dose increase led to a decrease in the serum inflammatory and interferon-inducible cytokines levels. This observation could be due to a reduction of drug diffusion and escape from the tumor site due to the precipitation of the drug inside the tumor leading to sustained release. IT delivery of TLR 7/8 dual agonist, MEDI9197, via a thermosensitive gel-based formulation was efficacious and could offer an alternate method of local drug delivery.
Copyright © 2017 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MEDI9197; TLR 7/8 dual agonist; intratumoral delivery; poloxamer 407; thermogel

Mesh:

Substances:

Year:  2017        PMID: 28456734     DOI: 10.1016/j.xphs.2017.04.041

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

1.  Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator.

Authors:  Ruolin Lu; Chad Groer; Peter A Kleindl; K Ryan Moulder; Aric Huang; Jordan R Hunt; Shuang Cai; Daniel J Aires; Cory Berkland; M Laird Forrest
Journal:  J Control Release       Date:  2019-06-04       Impact factor: 9.776

Review 2.  Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines.

Authors:  Geoffrey M Lynn; Richard Laga; Christopher M Jewell
Journal:  Cancer Lett       Date:  2019-06-08       Impact factor: 8.679

3.  Using nanoparticles for in situ vaccination against cancer: mechanisms and immunotherapy benefits.

Authors:  Michael-Joseph Gorbet; Akansha Singh; Chenkai Mao; Steven Fiering; Ashish Ranjan
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

Review 4.  The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy.

Authors:  Lingling Huang; Xiaoyan Ge; Yang Liu; Hui Li; Zhiyue Zhang
Journal:  Pharmaceutics       Date:  2022-06-10       Impact factor: 6.525

Review 5.  Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors.

Authors:  Sudhir Agrawal; Ekambar R Kandimalla
Journal:  Immunooncol Technol       Date:  2019-10-16

6.  Thermogelling properties of purified poloxamer 407.

Authors:  Amir Fakhari; Marta Corcoran; Alexander Schwarz
Journal:  Heliyon       Date:  2017-08-30

7.  Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.

Authors:  Stefanie R Mullins; John P Vasilakos; Katharina Deschler; Iwen Grigsby; Pete Gillis; Julius John; Matthew J Elder; John Swales; Elina Timosenko; Zachary Cooper; Simon J Dovedi; Andrew J Leishman; Nadia Luheshi; James Elvecrog; Ashenafi Tilahun; Richard Goodwin; Ronald Herbst; Mark A Tomai; Robert W Wilkinson
Journal:  J Immunother Cancer       Date:  2019-09-11       Impact factor: 13.751

8.  Development of a novel TLR8 agonist for cancer immunotherapy.

Authors:  Yuxun Wang; Heping Yang; Huanping Li; Shuda Zhao; Yikun Zeng; Panpan Zhang; Xiaoqin Lin; Xiaoxiang Sun; Longsheng Wang; Guangliang Fu; Yaqiao Gao; Pei Wang; Daxin Gao
Journal:  Mol Biomed       Date:  2020-09-10

Review 9.  Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy.

Authors:  Dhruv Varshney; Sherry Yue Qiu; Tyler P Graf; Kevin J McHugh
Journal:  AAPS J       Date:  2021-06-28       Impact factor: 4.009

10.  ABC triblock bottlebrush copolymer-based injectable hydrogels: design, synthesis, and application to expanding the therapeutic index of cancer immunochemotherapy.

Authors:  Farrukh Vohidov; Lauren E Milling; Qixian Chen; Wenxu Zhang; Sachin Bhagchandani; Hung V-T Nguyen; Darrell J Irvine; Jeremiah A Johnson
Journal:  Chem Sci       Date:  2020-06-01       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.